Physician profile
William Short
NPI 1841300340
$1,675.75
in general payments reported to CMS, 2019-2025
28 companies · $195 in 2025
The $195 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $332 · 2020: $221 · 2021: $391 · 2022: $221 · 2023: $176 · 2024: $139 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $509.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $264.38 | 2019-2024 | Ozempic, Rybelsus |
| Pfizer INC. | $242.45 | 2019-2025 | |
| Amgen INC. | $183.20 | 2019-2022 | |
| Lilly USA, LLC | $122.06 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Novartis Pharmaceuticals Corporation | $110.43 | 2019-2024 | |
| Abbvie INC. | $81.49 | 2022-2024 | Vraylar, Dalvance |
| Electromed, INC. | $75.84 | 2021-2022 | |
| Eisai INC. | $73.80 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $72.02 | 2021-2023 | Verquvo, Belsomra |
| Mylan Specialty L.P. | $40.98 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.49 | 2020-2021 | |
| Glaxosmithkline, LLC. | $35.40 | 2024-2025 | Pediarix, Penmenvy, Bexsero |
| Amarin Pharma, INC. | $29.50 | 2020-2021 | |
| Vapotherm INC | $29.40 | 2019 | |
| Kerecis Limited | $28.56 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $27.56 | 2021-2024 | Affinity |
| Convatec INC. | $26.43 | 2025 | |
| Nevro Corp. | $26.17 | 2023 | Senza |
| Astrazeneca Pharmaceuticals LP | $23.03 | 2020-2022 | |
| Grifols USA, LLC | $19.21 | 2019 | |
| Acadia Pharmaceuticals INC | $18.32 | 2022 | |
| Reprise Biomedical, INC. | $17.36 | 2025 | Miro3d |
| Otsuka America Pharmaceutical, INC. | $17.04 | 2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.88 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $14.66 | 2019 | |
| Corcept Therapeutics | $14.61 | 2025 | Korlym |
| Mimedx Group, INC. | $13.75 | 2025 | |
| Janssen Pharmaceuticals, INC | $11.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Short listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.